| scholarly article | Q13442814 |
| P50 | author | Antonio Fabrizio Nifosì | Q92212098 |
| Mariateresa Zuccarello | Q92212102 | ||
| Lorenzo Nifosì | Q92212106 | ||
| Vanessa Hervas Saus | Q92212110 | ||
| Gianfilippo Nifosì | Q92212114 | ||
| P2093 | author name string | Antonio Fabrizio Nifosì | |
| Gianfilippo Nifosì | |||
| Lorenzo Nifosì | |||
| Mariateresa Zuccarello | |||
| Vanessa Hervas Saus | |||
| P2860 | cites work | Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons | Q26771715 |
| Bevacizumab-related osteneocrosis of the jaw. | Q43194447 | ||
| Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors | Q44582801 | ||
| Osteonecrosis of the mandible associated with bevacizumab therapy. | Q45060836 | ||
| Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma | Q45069576 | ||
| Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone | Q46124362 | ||
| Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? | Q46136060 | ||
| Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab | Q46535211 | ||
| Unusual bevacizumab-related complication of an oral infection | Q46744805 | ||
| Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors | Q47672449 | ||
| Mammalian target of rapamycin as a therapeutic target in osteoporosis | Q48187280 | ||
| Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. | Q49990599 | ||
| The Role of Angiogenesis in Cancer Treatment. | Q50932310 | ||
| Metabolic regulation of osteoclast differentiation and function. | Q51005199 | ||
| Osteonecrosis of the jaw related to everolimus: a case report. | Q53313578 | ||
| Osteonecrosis of the jaw related to sunitinib. | Q54680163 | ||
| Osteonecrosis of the Jaw Related to Bevacizumab | Q60386785 | ||
| Osteonecrosis of the jaws and bevacizumab therapy: a case report | Q61775067 | ||
| Bevacizumab-induced laryngeal necrosis | Q82365307 | ||
| Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors | Q83390295 | ||
| Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw | Q83399039 | ||
| Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab | Q83689955 | ||
| Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab | Q84005848 | ||
| Sunitinib related osteonecrosis of jaw: a case report | Q84323419 | ||
| Osteonecrosis after administration of intravitreous bevacizumab | Q84561165 | ||
| A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit | Q84818261 | ||
| Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports | Q84940025 | ||
| Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus | Q26996169 | ||
| Structural mechanism for STI-571 inhibition of abelson tyrosine kinase | Q27627097 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients | Q34253684 | ||
| The multi-targeted kinase inhibitor sunitinib induces apoptosis in colon cancer cells via PUMA. | Q34389359 | ||
| Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. | Q35807838 | ||
| Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. | Q35978414 | ||
| A rare case of osteonecrosis of the jaw related to imatinib | Q36360226 | ||
| Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. | Q36385639 | ||
| Osteonecrosis of the jaw and oral hygiene: a case-control study from Condor Dental PBRN. | Q36816868 | ||
| Update on anti-CTLA-4 antibodies in clinical trials | Q36909389 | ||
| Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody | Q37051843 | ||
| Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. | Q37110398 | ||
| Osteonecrosis of the jaw associated with ziv-aflibercept | Q37525339 | ||
| Dissecting the role of mTOR: lessons from mTOR inhibitors | Q37652233 | ||
| Osteonecrosis of the jaw associated with everolimus: A case report | Q37701817 | ||
| Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients | Q37963138 | ||
| Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district | Q38583014 | ||
| Osteonecrosis of the jaw a new complication related to Ipilimumab. | Q38865775 | ||
| Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature | Q40270911 | ||
| Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. | Q40481345 | ||
| Bevacizumab-associated osteonecrosis of the jaw. | Q42536858 | ||
| Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? | Q42811436 | ||
| Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases | Q42943770 | ||
| Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. | Q43044764 | ||
| Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer | Q43111250 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| immunomodulation | Q27788458 | ||
| P304 | page(s) | 3-8 | |
| P577 | publication date | 2019-02-26 | |
| P1433 | published in | Journal of the Korean Association of Oral and Maxillofacial Surgeons | Q26842546 |
| P1476 | title | Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology | |
| P478 | volume | 45 |
Search more.